Nahdi Medicalالنهدي
- Price
- 96.50 SAR
- Fair value
- 77.74 SAR
- Discount to fair value
- −24%
- Mkt cap
- 12.54B
- P/E
- 15.1×
- P/B
- 4.57×
- EV
- 13.77B
- Div yield
- 5.80%
- ROE
- 30.3%
- Net margin
- 8.1%
Current price96.5SAR
Fair value (est., median)77.74SAR
UndervaluedFair valueOvervalued
+24.1% above fair valueWould need to fall ~19.4% to reach fair value.
Median ofDCF 98.95DDM 84.48Graham 55.4Residual Income 77.74Earnings Power 61.56
Health Check
46
Overall / 100
Good (66+)Caution (40–65)Risk (<40)
Rewards
- Strong return on equity (30.3%).
Risks
- Trades 24.1% above estimated fair value.
- Low fair-value confidence — methods disagree or data is thin.
- Dividend payout looks stretched.
Scores are computed automatically from the real financial statements (Value from fair value; the rest from growth, profitability, balance sheet and dividends). A decision aid, not investment advice.
Price, corporate actions & news
Demo series
D — DividendS — Split▲ good · ▼ bad newstap a marker for detailsDemo series
Growth & profitability
Revenue, net income and margin.
RevenueNet incomeNet margin %tap a bar for figures
Key figures
Covers 4 years · FY2022–FY2025
| Metric | FY'22 | FY'23 | FY'24 | FY'25 | TTM'26 |
|---|---|---|---|---|---|
| Revenue | 8.62B | 8.71B | 9.45B | 10.21B | — |
| Net Income | 887.81M | 892.62M | 820.72M | 830.74M | 811.20M |
| Net Margin | 10.3% | 10.2% | 8.7% | 8.1% | — |
| Operating Cash Flow | 1.67B | 1.32B | 1.49B | 1.13B | — |
| OCF Margin | 19.4% | 15.1% | 15.8% | 11.1% | — |
| Capital Expenditure | 275.23M | 384.51M | 384.50M | 417.62M | — |
| Free Cash Flow | 1.39B | 931.52M | 1.11B | 716.11M | — |
| FCF Margin | 16.2% | 10.7% | 11.7% | 7.0% | — |
| FCF Conversion | 156.9% | 104.4% | 134.9% | 86.2% | — |
| EPS (Diluted) | 6.83/sh | 6.87/sh | 6.31/sh | 6.39/sh | 6.24/sh |
| Dividend / Share | 2.31/sh | 5.50/sh | 5.50/sh | 5.60/sh | — |
Dividend return (if you buy today)if you buy today
Dividend yield5.80%
Dividend / share5.60
If you invest
Shares (≈)103
Est. annual income576.80
At this rate, dividends alone return your capital in ~17.2 years.
Dividend history
Dividend / share & historical yield (SAR).
Dividend / share yield %tap a bar for figures
Quarterly dividends & yield
Per-share dividends by quarter, full-year total, and yield on the year's average price · SAR
| Year | Q1 | Q2 | Q3 | Q4 | Full year | Yield (avg) |
|---|---|---|---|---|---|---|
| 2026 | — | — | — | — | — | — |
| 2025 | — | — | — | — | 5.60 | — |
| 2024 | — | — | — | — | 5.50 | — |
| 2023 | — | — | — | — | 5.50 | — |
| 2022 | — | — | — | — | 2.31 | — |
Valuation breakdown
Fair value = median of the applicable methods (DCF، DDM، Graham، Residual Income، Earnings Power).
Each method below is a different lens on the same company — no single method dominates the result.
Discounted Cash Flow
Values the company from the future cash it's expected to generate. · Tap to adjust assumptions
98.95
Dividend Discount Model
Values the share from the dividends it's expected to keep paying. · Tap to adjust assumptions
84.48
Graham Number
A conservative benchmark built from earnings and book value. · Tap to adjust assumptions
55.40
Residual Income (justified P/B)
Values the profit the company earns above the cost of its equity. · Tap to adjust assumptions
77.74
Earnings Power Value
Values today's earning power as-is, assuming no growth. · Tap to adjust assumptions
61.56
DCF only is anchored on FY2025 — the latest year with positive cash flow that supports a value. The other methods (DDM, Graham, RIM, EPV) use current / normalized figures.
Fair Value (median)77.74
▸ Show assumptions▾ Assumptions
- Effective discount rate
- 9.83%
- CAPM cost of equity
- 10.50%
- Risk-free rate
- 4.50%
- Equity risk premium
- 6.00%
- DCF growth (stage 1)
- 8.00%
- DCF terminal growth
- 3.00%
- DCF forecast years
- 5
- DDM dividend growth
- 3.00%
Tune these per company in the Hajras Odoo backend; values recompute automatically.
Wealth simulator
What if you'd invested in Nahdi Medical regularly?
Starting year
Not enough history to simulate.
Community Notes0
No notes yet. Be the first to share a thesis.